Suraksha Diagnostic has scheduled its 21st Annual General Meeting for Tuesday, September 22, 2026. The meeting will be conducted via Video Conferencing or Other Audio-Visual Means.

The Board of Directors recommended a final dividend of ₹0.50 per equity share of face value ₹2 each for the financial year ended March 31, 2026. This payout is subject to approval by shareholders at the upcoming meeting.

Meeting Logistics and Voting

The AGM will commence at 11:30 am IST. Members participating through VC/OAVM will be reckoned for the purpose of quorum under Section 103 of the Companies Act, 2013.

Shareholders holding shares as on the cut-off date of September 9, 2026, are eligible to vote electronically. The remote e-voting period opens on Saturday, September 12, 2026, at 9:00 am and closes on Tuesday, September 15, 2026, at 5:00 pm. Voting services are provided by National Securities Depository Limited.

Members who have not registered their email addresses with the company or depositories must do so to cast votes or access the Annual Report. Physical copies of the notice and annual report will only be dispatched upon specific request.

Dividend Disbursement

If declared, the final dividend will be paid electronically after tax deduction at source. Shareholders without registered bank details with their respective Depository Participants are advised to update their information to ensure seamless receipt of dividends.

Suraksha Diagnostic Limited reported a strong start to FY27, posting a consolidated net profit of ₹128 crore for the quarter ended June 30, 2026, compared to ₹92 crore in the same period of FY26. The healthcare diagnostics firm saw its total income rise by 21% year-on-year to ₹887 million (₹88.7 crore), while EBITDA grew by 28% to ₹315 million (₹31.5 crore). The EBITDA margin expanded to 36% from 34% previously, reflecting improved operating leverage as fixed costs were spread over higher volumes.

The Board of Directors approved the unaudited standalone and consolidated financial results during a meeting held on August 12, 2026. Joint Managing Director and CEO Ritu Mittal signed off on the disclosure, which was filed with the BSE and NSE under Regulation 47 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. An earnings call was subsequently held on August 13, 2026, where management discussed the financial performance and strategic initiatives.

Financial Performance

The company’s revenue growth was accompanied by a sharp improvement in operating margins. While total income increased moderately, the EBITDA expansion indicates better cost management or higher-margin mix in its diagnostic services. The tangible net worth also strengthened, rising to ₹880.22 crore as of June 30, 2026, from ₹807.13 crore a year ago.

Operational Updates

During Q1FY27, Suraksha commissioned one hub and three spoke centers, bringing its total network to 72 centers. The company has extended its footprint beyond West Bengal with the commissioning of a hub center in Jharkhand, with another hub planned for Tripura. Management expects to add three more hubs and six spoke centers in the current financial year, aiming to reach 100 centers by FY28.

Patient volume stood at 0.38 million, with 2.10 million tests performed. Tests per patient averaged 5.56, while revenue per patient was ₹2,321. Mature centers (older than two years) delivered an EBITDA margin of 40.9%, while centers under two years old turned profitable with a 6.5% EBITDA margin, improving from negative 5.5% in the previous quarter.

Genomics and Technology Initiatives

Suraksha Genomics recorded revenue of ₹13.7 million, registering a 136% year-on-year growth. The segment is currently split 80% B2C and 20% B2B, with margins estimated at 15-20%. Management highlighted the acquisition of Genexus equipment for fast genome sequencing, reducing oncology study turnaround time from 14-17 days to 48 hours. Over the past three years, the company has invested approximately ₹22 crore in genomic capacity.

New initiatives include a blood test for Alzheimer’s disease and an AI-driven project for early detection from plain brain MRI, developed in collaboration with CSIR. Management noted that genomics remains an underpenetrated market in Eastern India, with significant potential for growth as oncology treatments become more personalized.

What the Numbers Show

The divergence between revenue growth (21%) and profit expansion (40%) highlights strong operational leverage. Mature centers contributed significantly to this expansion, with their EBITDA margin reaching 40.9%. Additionally, the shift from Siemens to Roche for biochemistry business has helped improve gross margins through better negotiated deals. The profitability of newer centers (under two years) turning positive signals successful ramp-up execution, which should further boost overall margins as these centers scale.

The full format of the financial results is available on the stock exchange websites and the company’s official portal.